Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057117 | 0.81 | KDM4E (0.54) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL13567005 | 0.81 | KDM4E (0.54) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL12677487 | 0.79 | KDM4E (0.52) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL24158355 | 0.77 | TAS1R3 (0.42) | PAOXPLA2G2CPLA2G2A | |
| SCHEMBL292767 | 0.77 | CRAT (0.34) | PAOXKDM4EMAPK1HIF1APLA2G2C | |
| SCHEMBL13023036 | 0.76 | KDM4E (0.52) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL11535406 | 0.74 | KDM4E (0.48) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL12910863 | 0.73 | FOLH1 (0.50) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL13936433 | 0.73 | KDM4E (0.58) | PAOXKDM4EMAPK1HIF1AFOLH1 | |
| SCHEMBL432565 | 0.73 | KDM4E (0.58) | PAOXKDM4EMAPK1HIF1AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273343-B2 | Protein-polymer conjugates | PHARMAESSENTIA CORP. (TW) | 2012-09-25 | — | — | US | disclosed |
| US-8143214-B2 | Protein-polymer conjugates | PHARMAESSENTIA CORP. (TW) | 2012-03-27 | — | — | US | disclosed |
| US-20110262380-A1 | THEAPEUTIC USE OF PROTEIN-POLYMER CONJUGATES | PHARMAESSENTIA CORP. (TW) | 2011-10-27 | — | — | US | disclosed |
| US-20110098451-A1 | PEPTIDE-POLYMER CONJUGATES | PHARMAESSENTIA CORP. (TW) | 2011-04-28 | — | — | US | disclosed |
| US-20100029907-A1 | PEPTIDE-POLYMER CONJUGATES | PHARMAESSENTIA CORP. (TW) | 2010-02-04 | — | — | US | disclosed |
| US-20090053177-A1 | PROTEIN-POLYMER CONJUGATES | PHARMAESSENTIA CORP. (TW) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029907-A1 | PEPTIDE-POLYMER CONJUGATES | IFNG, EPOR, IFNAR1 | PAOX 3279/4885KDM4E 4482/4885MAPK1 3789/4885 |
| US-20110262380-A1 | THEAPEUTIC USE OF PROTEIN-POLYMER CONJUGATES | MPL, BCR, CD47 | PAOX 2293/4885KDM4E 2349/4885MAPK1 3452/4885 |
| US-20110098451-A1 | PEPTIDE-POLYMER CONJUGATES | EPOR, NPPA, ENPEP | PAOX 3568/4885KDM4E 3758/4885MAPK1 3355/4885 |
| US-20090053177-A1 | PROTEIN-POLYMER CONJUGATES | HAVCR2, CD2BP2, PLTP | PAOX 2492/4885KDM4E 3016/4885MAPK1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.